October 2024 – Page 21 – Talk Bio

Actionable Insights Powered by AI

Pfizer’s Former Executives Back Activist Investor Starboard’s Revamp Plan

7 months ago talkbio0Tagged activist investor, Albert, Bourla, Corporate, Drug Industry, Frank D'Amelio, governance, Pfizer, Starboard Value

Pfizer, Starboard Value, activist investor, Ian Read, Frank D’Amelio, Albert Bourla, pharmaceutical industry, corporate governance

Compounding Pharmacies Challenge FDA’s Decision to End Eli Lilly’s GLP-1 Drug Shortage

7 months ago talkbio0Tagged Drug Shortage, Eli, Eli Lilly, Glucagon-Like Peptide 1, Pharmacy facility, United States Food and Drug Administration

Eli Lilly, GLP-1 drug, FDA, compounding pharmacies, drug shortage, lawsuit

Novo Nordisk and Viatris Settle Patent Dispute Over Ozempic and Wegovy, Keeping Generic Entry Date Undisclosed

7 months ago talkbio0Tagged Agreement, Generic Entry, Legal patent, Mylan, Nordisk, Settlement and Resettlement, Viatris, Wegovy

Novo Nordisk, Viatris, Mylan Pharmaceuticals, Ozempic, Wegovy, Patent Dispute, Generic Entry Date, Settlement Agreement

Merck & Co. and Mestag Therapeutics Collaborate on $1.9 Billion Fibroblast Therapy Deal for Inflammatory Diseases

7 months ago talkbio0Tagged Co., Drug Delivery Systems, Drug/, Fibroblast therapies, Identification (Psychology), Inflammatory disorder, Raft

Merck & Co., Mestag Therapeutics, Fibroblast therapies, Inflammatory diseases, $1.9 billion deal, RAFT platform, Drug target identification

Ceribell Pursues $101M Nasdaq IPO for Revolutionary Seizure-Spotting Headset

7 months ago talkbio0Tagged Brain-Reading Technology, Ceribell, emergency seizure care, IPO, Nasdaq, Seizure-Spotting Headset

Ceribell, Seizure-Spotting Headset, Nasdaq IPO, Emergency Seizure Care, Brain-Reading Technology

Scholar Rock Seeks $275M Funding Following Successful SMA Therapy Trial

7 months ago talkbio0Tagged Clinical Trials, pipeline, reshuffle, Scholar Rock, SMA, Spinal Muscular Atrophy, Vincerx

Scholar Rock, funding, SMA therapy, clinical trial, Vincerx, pipeline reshuffle

Black Diamond Therapeutics Refocuses on Lung Cancer Drug BDTX-1535 Amid Workforce Reduction

7 months ago talkbio0Tagged BDTX-1535, Black Populations, Diamond Therapeutics, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Mutation, Protein-tyrosine kinase inhibitor, Tagrisso

Black Diamond Therapeutics, workforce reduction, lung cancer drug, BDTX-1535, EGFR mutations, Tagrisso, tyrosine kinase inhibitor

Judo Bio Launches with $100M to Pioneer Kidney-Targeted siRNA Therapies

7 months ago talkbio0Tagged genetic medicines, Judo Bio, Kidney Diseases, megalin-STRIKERS, oligonucleotide medicines, RNA, Small Interfering, Strikes, Employee

Judo Bio, siRNA therapies, kidney diseases, oligonucleotide medicines, STRIKE platform, megalin-STRIKERS, renal diseases, genetic medicines.

Scholar Rock’s Stock Skyrockets 300% Following Successful Phase III Trial of Apitegromab for Spinal Muscular Atrophy

7 months ago talkbio0Tagged apitegromab, Biologics License Application, MAA, Phase 3 Clinical Trials, Scholar Rock, SMA, Spinal Muscular Atrophy, Stock Surge

Scholar Rock, Spinal Muscular Atrophy (SMA), Apitegromab, Phase III Trial, Stock Surge, Biologics License Application (BLA), Marketing Authorisation Application (MAA)

Judo Bio Launches with $100 Million to Revolutionize Kidney Drug Delivery

7 months ago talkbio0Tagged biotech startup, Judo Bio, kidney drug

Judo Bio, Kidney drug delivery, Biotech startup, Pharmaceutical innovation, $100 million funding